Angiotensin Ii
Brand Names: Giapreza
Methodology & AI Transparency ⓘ
Angiotensin Ii Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1.
- 2 Real-world patient consensus: 84% patient "Worth It" rating across 13 anonymous logs for Angiotensin Ii (RxNorm 1999007).
- 3 Typical cash cost range: Dispensing cost comparison spans $142.15 mail/discount cash up to $348.27 uninsured retail (federal NADAC $3.3000).
- 4 Top reported side effects / signs: Most commonly reported Angiotensin Ii tolerability events: nausea (8.5%), headache (7.1%), dizziness (6.2%).
Ask our AI Specialists anything about Angiotensin Ii
Angiotensin Ii Mechanism, CYP450 Pathways & DailyMed Monograph
1. Indications and usage giapreza: increases blood pressure in adults with septic or other distributive shock . GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. ( 1 )
12.1. Mechanism of Action Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca 2+ /calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.
With Terminal t½ estimated at 7–18 hrs depending on renal/hepatic reserve (Angiotensin Ii) residence kinetics and Complete (~100%) parenteral systemic delivery for Angiotensin Ii (2.5 mg/mL Injection) bioavailability, Angiotensin Ii undergoes mixed metabolic conjugation and unchanged urinary excretion across angiotensin ii regimens and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after angiotensin ii administration.
Standard adult regimens span 2.5 mg/mL Injection, .5 mg/mL Injection. Prescribers screen specifically against contraindications none.; prior anaphylaxis, angioedema, or severe hypersensitivity to angiotensin ii or angiotensin ii excipients, while community micro-logs most frequently note nausea (8.5% of reports), headache (7.1% of reports), dizziness (6.2% of reports).
Combining Angiotensin Ii with ACE inhibitors, ARBs, or aldosterone blockers can shift serum potassium and eGFR.
Avoid overlapping vasoconstrictor prescriptions alongside Angiotensin Ii to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS None.
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Angiotensin Ii or Angiotensin Ii excipients
Logged Side-Effect Incidence (13 Reports)
Angiotensin Ii Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Angiotensin Ii)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Randomized trials of telmisartan versus active controls for insulin resistance in: What a 2,033-Participant Study Found When data from all the 33 trials were pooled, telmisartan was associated with statistically significant reductions in percent changes of insulin levels (-10.92%; -15.60% to -6.23%; P < .00001) and HOMA-IR (-15.89%; -22.01% to... Journal of the American Society of Hypertension : JASH • 2014-08-15 • Meta-Analysis | N = 2,033 | 99/100 | PMID 25151319 ↗ |
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on A clinical trial in type 2 diabetic: What a 1,715-Participant Study Found This large-scale international trial should help define the clinical course and standards of care for hypertensive adults with type 2. American journal of kidney diseases : the official journal of the National Kidney Foundation • 2001-10-15 • Randomized Controlled Trial | N = 1,715 | 96/100 | PMID 11576953 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
Angiotensin Ii Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.3000/unit (~$99.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $348.27 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $142.15 / mo | View logs ↓ |
Angiotensin Ii Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Angiotensin Ii RxNorm Concept ID | 1999007 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.3000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $348.27 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $142.15 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Angiotensin Ii Patient Community, Cohort Filters & Dosage Logs
Cross-verified Angiotensin Ii (vasoconstrictor) monograph synthesizing RxNorm 1999007, openFDA FAERS signals, and $142.15–$348.27 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Angiotensin Ii community threads and patient logs by age, biological sex, dosage, and treatment duration.